If the health crisis has propelled Pfizer, BioNTech and Moderna to the forefront, the race for vaccines and treatments has been an obstacle course for several heavyweights in the pharmaceutical industry.
Sanofi, world number four in vaccines, is one of them.
The first French laboratory will not have succeeded in releasing its anti-Covid serum this year, showing several delays.
A blow in terms of image, public opinion not having digested that France does not have "its" vaccine.
Sanofi is still betting on positioning as a reminder but should only get a small piece of the pie.
Disappointment for AstraZeneca
If its British ally GSK - which is developing the adjuvant - has just obtained the green light from Brussels for Xevudy, an early treatment of Covid, it has not performed well either. The world number two in vaccines has had to put an end to its collaboration with the Chinese Clover Biopharmaceuticals.
He still has a second generation vaccine project with German biotech ...
This article is for subscribers only.
You have 68% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in